You have no authority here, Jackie Weaver
- Apr 3, 2020
We've been over this in the other thread. The data on zinc + ionophore is so thin that it amounts to nothing at all. What is particularly relevant to this is also that virtually nobody in the field thinks the relevant mechanism of action of HCQ for covid-19 is as an ionophore anyway. e.g.The only thing I've seen remdesivir is useful for is lowering a hospital stay, nothing shown to lower mortality rates. How are you gonna say there's more data showing the usefulness of remdesivir over HCQ? I linked to a 8,000+ patient study of HCQ. Also, an ionophore + zinc has been shown to hamper virus replication with SARS-COV-1, which is extremely similar to SARS-COV-2. Here's a study here and here that show zinc with an ionophore helps vs only taking an ionophore (like HCQ) or only taking zinc. HCQ helps because it lets the zinc into the cells to interfere with virus replication. HCQ also helps with the cytokine storm. Vitamin C with quercetin makes quercetin into an ionophore so you can substitute out HCQ out for those.
There are lots and lots of studies on HCQ. Some of them show an effect and some of them do not: this is normal. It just so happens all the best ones suggest not; or at least, not enough benefit to outweight the downsides and make it worth the bother. Consequently, the consensus has only grown stronger that HCQ is not useful. e.g.
No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19 — RECOVERY Trial
Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020
This randomized trial compares the effects of hydroxychloroquine vs placebo on clinical status at 14 days (home, requiring noninvasive or invasive ventilation or extracorporeal membrane oxygenation, hospitalized, died) among adults hospitalized with coronavirus disease 2019 (COVID-19).
The advantage of remdesevir reducing hospital time is that if part of the problem is the stress on the health service from people occupying hospital beds, cutting the average stay from 15 to 11 is a plus even if it makes no difference to mortality. One way or another, there is no "competition" between HCQ and remdesevir. There was urgent need for covid-19 medications, and it was deemed worth giving remdesevir a go despite the shaky evidence. It will all shake out in the long run.
Er, no. That's very mid-2020. The case for masks has gone up as the case for HCQ has gone down.There's more evidence supporting these treatments than there is evidence supporting masks.